Experimental 'Off-the-Shelf' cell therapy targets tough blood cancer
NCT ID NCT07139509
Summary
This early-stage study is testing a new type of cell therapy for adults with multiple myeloma that has returned or stopped responding to standard treatments. The therapy uses immune cells (CAR-T cells) from donated umbilical cord blood, modified to attack two targets on cancer cells. The main goals are to find a safe dose and understand the side effects in 18 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Xi'an No.3 Hospital
RECRUITINGXi’an, Shanxi, 710016, China
Conditions
Explore the condition pages connected to this study.